HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics’ investigational novel conditionally activated IL-2 pro-drug WTX-124
Tuesday, May 20, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: A patient at HonorHealth Research Institute has achieved remission from advanced skin cancer for over a year after participating in a clinical trial for Werewolf Therapeutics' WTX-124, a novel conditionally activated IL-2 pro-drug. This promising outcome highlights the potential effectiveness of this investigational treatment in managing advanced skin cancer.
Price reaction · baseline $1.105 (2025-05-20T13:49:00.000Z) · hit during market hours · clean, no other HOWL news in the window
day 0 close · peak
+3.2%
Market Sentiment Analysis
POSITIVE FACTORS
Patient with advanced skin cancer in remission for over a year.
Successful clinical trial of WTX-124 by Werewolf Therapeutics.
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
15%
average across 6 past catalysts
Lead asset
WTX-330
Phase 1 · Advanced or Metastatic Solid Tumors
Full Press Release Details
May 20, 2025
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics’ investigational novel conditionally activated IL-2 pro-drug WTX-124
WATERTOWN, Mass., May 20, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)
Share this article:
facebook-icon
twitter-icon
linked-in-icon
Frequently Asked Questions
What is WTX-124?
WTX-124 is an investigational novel conditionally activated IL-2 pro-drug.
How long has the patient been in remission?
The patient has been in remission for more than a year.
Which institute conducted the clinical trial?
The clinical trial was conducted at HonorHealth Research Institute.